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OBJECTIVES We sought to determine the frequency and timing of complications at our institution when
surgery was performed within two months of coronary stent placement.
BACKGROUND The optimal delay following coronary stent placement prior to non-cardiac surgery is
unknown.
METHODS We analyzed the Mayo Clinic Percutaneous Coronary Intervention and Surgical databases
between 1990 and 2000 and identified 207 patients who underwent surgery in the two
months following successful coronary stent placement.
RESULTS Eight patients (4.0%) died or suffered a myocardial infarction or stent thrombosis. All 8
patients were among the 168 patients (4.8%, 95% confidence interval [CI] 2.1 to 9.2)
undergoing surgery six weeks after stent placement; the frequency of these events ranged from
3.8% to 7.1% per week during each of the six weeks. No events occurred in the 39 patients
undergoing surgery seven to nine weeks after stent placement (0%, 95% CI 0.0 to 9.0).
CONCLUSIONS These data suggest that, whenever possible, non-cardiac surgery should be delayed six weeks
after stent placement, by which time stents are generally endothelialized, and a course of
antiplatelet therapy to prevent stent thrombosis has been completed. (J Am Coll Cardiol
2003;42:234–40) © 2003 by the American College of Cardiology Foundation
Stent thrombosis is a highly morbid complication of coro-
nary stent placement. Most cases of stent thrombosis result
in Q-wave myocardial infarction (MI) or death (1–7). With
the use of combined antiplatelet therapy after stent place-
ment (aspirin and thienopyridine) the frequency of stent
thrombosis is extremely low, generally 1%, and it usually
occurs in the first few days following stent placement
(1,8,9). However, the impact of non-cardiac surgery on the
frequency and timing of stent thrombosis is unclear. It
follows, therefore, that the optimal delay following coronary
stent placement prior to non-cardiac surgery is unknown.
The only previous study addressing this issue reported a
mortality rate of 32% among 40 patients when surgery was
performed 2 weeks following stent placement; in that
study, neither death, MI, nor stent thrombosis occurred
when surgery was performed after a2 week delay (10). We
examined the frequency and timing of complications at our
institution when non-cardiac surgery was performed within
two months of coronary stent placement.
METHODS
We performed a retrospective analysis of the Percutaneous
Coronary Intervention database and the General Surgery
database at Mayo Clinic and identified 207 patients who
underwent non-cardiac surgery within 60 days of coronary
stent placement. Surgical procedures included in this anal-
ysis were those that required a significant incision and had
the potential for perioperative bleeding. Procedures such as
joint aspirations, endoscopy, and skin biopsies, among
others, were not included in this analysis. All patients
undergoing percutaneous coronary revascularization at the
Mayo Clinic are followed up according to a protocol
approved by the Mayo Clinic Institutional Review Board.
The Percutaneous Coronary Intervention database includes
baseline and in-hospital demographic, clinical, and angio-
graphic data.
Definitions. Successful stent placement was defined as
20% reduction in the lumen diameter stenosis, resulting in
a final residual stenosis within the stent of 50% by visual
estimation, with achievement of Thrombolysis in Myocar-
dial Infarction (TIMI) flow grade 3 and without the
in-laboratory occurrence of death, Q-wave MI, or require-
ment of coronary artery bypass graft (CABG) surgery (11).
A perioperative MI was considered to have occurred when
at least two of the following three criteria were met: 1) chest
pain 30 min; 2) persistent electrocardiographic (ECG)
changes suggestive of ischemia; or 3) characteristic eleva-
tions in serum creatine kinase (CK) levels or CK-MB
isoform (2 times normal). Q-wave MI was defined as two
of the above criteria with new pathologic Q waves in the
coronary distribution of the stented artery. Thrombus was
considered to be present when one or more lumen-filling
defects in a coronary artery were visualized with contrast
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present on three sides. Dissections were diagnosed when
contrast staining was apparent within the vessel wall, and
they were classified according to the National Heart, Lung,
and Blood Institute (NHLBI) classification system (12).
Single-vessel disease was defined as the presence of a 70%
lesion in one of the three major coronary arteries or their
major branches. Multivessel disease was defined as the
presence of a 70% lesion in a major coronary artery or its
major branches and a 50% lesion in a second coronary
artery or its major branches. The angiographic severity of
coronary artery stenoses was assessed visually using two
orthogonal views. Lesions were classified according to the
modified American Heart Association/American College of
Cardiology lesion classification scheme by the interventional
cardiologist performing the angioplasty procedure, immedi-
ately before the procedure was performed (13). Using a
modified Simpson’s rule, left ventricular ejection fractions
were calculated from ventriculography performed in a 30°
right anterior oblique projection (14).
Intracoronary stent implantation technique. Coronary
angioplasty and intracoronary stent implantation were per-
formed using standard percutaneous techniques via the
femoral, brachial, or radial artery. In the earlier time period,
8F guide catheters and over-the-wire systems were utilized.
In the more recent study period, rapid-exchange systems
and 6F and 7F guide catheters were more commonly used.
Intravascular ultrasound was used infrequently (10%), at
the discretion of the operator.
Medical therapy. All patients received pre-procedural oral
aspirin (325 mg) and intravenous heparin to achieve an
activated clotting time of approximately 300 s, or approxi-
mately 250 s if a platelet glycoprotein IIb/IIIa inhibitor was
used. In patients receiving a combination of warfarin and
aspirin, warfarin was initiated the evening of the procedure
and intravenous heparin was continued until the Interna-
tional Normalized Ratio (INR) was 2.0. In patients
receiving ticlopidine (which became routine in early 1995),
the first dose was administered before the procedure (gen-
erally within 1 h), with an initial loading dose of 500 mg,
and a 250-mg dose was administered later that evening
followed by 250 mg twice a day for two to four weeks, in
addition to aspirin 81 to 325 mg daily. After March 1998,
clopidogrel was substituted for ticlopidine and was given as
a loading dose of 300 mg either immediately before or
during the procedure, followed by 75 mg daily for two to
four weeks.
Bleeding complications. The hospital charts of all patients
included in the study were reviewed; only bleeding data
from three charts (1.4%) were unavailable for review. The
following data were collected from the surgical, anesthesia,
nursing, and physician’s notes and reports: date of percuta-
neous coronary intervention and surgery, type of surgery,
interval between last dose of antiplatelet agent (aspirin and
thienopyridine) and warfarin (and INR level), surgical
procedure, estimated blood loss, presence of excessive sur-
gical bleeding (defined as persistent bleeding despite ade-
quate use of electrocautery and suture, or decreased clotting
time within the surgical field), and perioperative transfusion
requirements.
End points. The frequency of death, Q-wave MI, non–Q-
wave MI, stent thrombosis, surgical bleeding complications,
and repeat revascularization with either CABG or repeat
angioplasty of the target vessel were analyzed. The earliest
and latest dates that patients in this study received stents
were July 31, 1990, and June 23, 2000.
Statistical analyses. Data are presented as the mean  1
SD, or percentages. Comparisons between groups were
made using one-way analysis of variance, the Pearson
chi-square test, or the Wilcoxon rank-sum test, as appro-
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CI  confidence interval
INR  International Normalized Ratio
MI  myocardial infarction
NHLBI  National Heart, Lung, and Blood Institute
TIMI  Thrombolysis In Myocardial Infarction
Table 1. Baseline Clinical Characteristics of Patients in the Entire Study Group, and Those
With and Without an Adverse Event Analyzed Separately
All Patients
(n  207)
Patients With
an Event
(n  8)
Patients Without
an Event
(n  199) p Value†
Age (yrs)* 66.9  9.8 67.1  12.0 66.9  9.8 0.95
Male patients (%) 65.2 75.0 64.8 0.55
Prior myocardial infarction (%) 51.7 50.0 51.8 0.92
Prior CABG (%) 20.8 25.0 20.6 0.76
History of smoking 65.5 50.0 66.2 0.35
History of hypercholesterolemia
(%)
64.4 62.5 64.5 0.91
History of hypertension (%) 69.3 71.4 69.2 0.90
History of diabetes (%) 27.5 25.0 27.6 0.87
Pre-procedural shock (%) 5.5 12.5 5.2 0.38
*Continuous variables are presented as mean values  SD. †The p values relate to comparisons between patients with and
without an event.
CABG  coronary artery bypass graft surgery.
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priate. All analyses were performed using SAS software
(SAS Inc., Cary, North Carolina). One-way analysis of
variance was employed for the variables that are summarized
using mean  SD. The Pearson chi-squared test was used
for binary response variables, summarized with percentages.
The Wilcoxon rank-test was used for the discrete ordinal
variables, summarized with percentages for each level.
RESULTS
Baseline characteristics. The 207 patients included in this
study underwent surgery 1 to 60 days following stent
implantation. The baseline clinical and postprocedural an-
giographic characteristics of all 207 patients in the study
population, and of patients grouped into those who did (n
8) and did not (n  199) suffer a major adverse event, are
summarized in Table 1.
Adjunctive medical therapy. The medical therapies re-
ceived at discharge (Table 2) did not differ between patients
who did and did not suffer an adverse event after non-
cardiac surgery. Only 21% of patients (n  43) were
discharged while receiving warfarin; 75% of patients (n 
155) were discharged while receiving aspirin and a
thienopyridine.
Procedural characteristics. The procedural characteristics
of the revascularization procedure are displayed in Tables 3
and 4. Patients who suffered a major adverse event had a
significantly more severe residual stenosis (17  17% vs. 9
 17%, p  0.04) than those who did not have an event.
Surgical procedures. Types of surgical procedures are
listed in Table 5. Most patients in the study underwent
vascular surgery. None of the patients who underwent
genitourinary, head and neck, or breast surgery in this study
suffered a major adverse event, although the number of such
patients was relatively small.
Adverse events. Eight of 207 patients had major adverse
cardiac events. Of these, six patients died, two of whom
suffered or were suffering an MI before dying (Table 6).
One patient had a non-fatal MI. The percentage of patients
suffering a major adverse event and the number of weeks
that surgery was performed after stent placement are dis-
played in Figure 1.
Bleeding complications from surgery. At the time of
surgery, 54 patients (26%) received both aspirin and thien-
opyridine, 29 patients (14%) received aspirin and had
received the last dose of thienopyridine within the previous
10 days, 104 patients (51%) received aspirin only, 13
Table 2. Post-Discharge Medication Use in the Study Group
All Patients
(n  207)
Patients With
an Event
(n  8)
Patients Without
an Event
(n  199) p Value
Abciximab* 22.3 12.5 21.6 0.54
Aspirin 95.2 100.0 95.0 0.52
Ticlopidine 37.7 25.0 38.2 0.45
Clopidogrel 40.1 50.0 39.7 0.56
Beta-blocker 62.8 50.0 63.3 0.44
ACE inhibitor 28.5 37.5 28.1 0.57
Calcium channel blocker 33.3 25.0 33.7 0.61
*Used during the percutaneous coronary intervention.
ACE  angiotensin-converting enzyme.
Table 3. Baseline Angiographic Characteristics of the Study Group
All Patients
(n  207)
Patients With
an Event
(n  8)
Patients Without
an Event
(n  199) p Value
Vessel treated
Left anterior descending 44.0 50.0 43.7 0.73
Left circumflex 30.0 50.0 29.1 0.21
Right coronary artery 30.9 37.5 30.7 0.68
Saphenous vein graft 10.1 0.0 10.6 0.33
Number of vessels dilated 0.06
1 84.5 62.5 85.4
2 14.5 25.0 14.1
3 1.0 12.5 0.5
Initial luminal diameter stenosis (%)* 83.8  13.8 80.8  17.1 84.0  13.5 0.35
Initial TIMI flow* 0.37
0 8.2 7.7 8.3
1 3.9 0.0 4.1
2 14.7 7.7 15.1
3 73.2 84.6 72.5
Reference diameter (mm)* 3.3  0.7 3.2  0.4 3.4  0.7 0.44
*Denominator is number of treated lesions.
TIMI  Thrombolysis In Myocardial Infarction.
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patients (6.3%) received no antiplatelet agents, and 4 pa-
tients (2.0%) received aspirin and warfarin, all of whom had
an INR 1.7 (Table 7). Only two patients were described
by either the surgeon or the anesthesiologist as having
excessive bleeding during surgery; one patient received both
aspirin and ticlopidine, and the second patient received
aspirin alone. None of the four patients with an elevated
INR due to warfarin at the time of surgery had clinically
significant bleeding. No major clinical events were attrib-
uted to bleeding complications. A total of 67 patients (33%)
received a red blood cell transfusion during or immediately
after the surgical procedure; platelet transfusions were ad-
ministered to six patients. The transfusion requirements in
relation to the anticoagulation/antiplatelet regimen are enu-
merated in Table 7. There was no apparent association
between transfusion requirements and time of discontinua-
tion of antiplatelet and anticoagulant therapy. The majority
of transfusions in patients receiving the dual antiplatelet
regiment (aspirin and thienopyridine) were performed for
blood loss that had occurred before surgery secondary to
vascular complications related to the percutaneous coronary
intervention, such as hematoma or pseudoaneurysm.
DISCUSSION
The most important finding of this study is that the risk of
stent thrombosis and other major complications after non-
cardiac surgery is greatest in the first six weeks after stent
placement and less thereafter, although due to the small
number of events and the wide confidence intervals around
these point estimates, the findings of this study should be
regarded as suggestive and not definitive. The overall rate of
complications was lower than in an earlier study of this issue
(10).
Stent thrombosis. Stent thrombosis has been occurring
less frequently in recent years than ever before, in part
because of the combination therapy with both aspirin and a
thienopyridine, and because of better understanding about
how stents should be deployed (15–18). However, when
stent thrombosis occurs, it usually results in either Q-wave
MI or death (1,8,9). Therefore, risk factors associated with
stent thrombosis should be identified and steps taken to
avoid this highly morbid complication.
Effect of surgery on hemostasis. Surgery promotes throm-
bosis, and by its very nature requires thrombosis; all patients
Table 4. Final Angiographic Characteristics of the Study Group
All Patients
(n  207)
Patients With
an Event
(n  8)
Patients Without
an Event
(n  199) p Value
Number of stents placed 0.48
1 58.5 50.0 58.8
2 30.4 25.0 30.7
3 8.2 25.0 7.5
4 2.9 0.0 3.0
Residual dissection 44.4 37.5 44.7 0.69
Residual stenosis (%)* 9  17 17  17 8  17 0.04
TIMI flow post procedure* 0.73
0 0.3 0.0 0.4
1 0.3 0.0 0.4
2 0.0 0.0 0.0
3 99.3 100.0 99.3
*Denominator is number of treated lesions.
TIMI  Thrombolysis In Myocardial Infarction.
Table 5. Type of Surgical Procedure
Type of Surgery
Antithrombotic Regimen
All Groups
(n  204)
n (%)
Aspirin and a
Thienopyridine
(n  54)
Aspirin and Last
Thienopyridine
<10 Days Before
Surgery (n  29)
Aspirin and
Warfarin
(n  4)
Aspirin Alone
(n  104)
No Antiplatelet
or Anticoagulant
Therapy for >10
Days (n  13)
Vascular repair
(PCI complication)
68 (33.3%) 31 (57.4%) 5 (17.2%) 3 (75.0%) 27 (25.9%) 2 (15.3%)
Vascular surgery 50 (24.5%) 8 (14.8%) 5 (17.2%) 1 (25.0%) 33 (31.7%) 3 (23.0%)
Orthopedic 16 (7.8%) 2 (3.7%) 3 (10.3%) — 9 (8.6%) 2 (15.3%)
Genitourinary 12 (5.8%) — 1 (3.4%) — 9 (8.6%) 2 (15.3%)
GI—abdominal 17 (8.3%) 5 (9.2%) 3 (10.3%) — 8 (7.6%) 1 (7.6%)
Thoracic 15 (7.3%) — 5 (17.2%) — 9 (8.6%) 1 (7.6%)
Head and neck 9 (4.4%) 3 (5.5%) 3 (10.4%) — 2 (1.9%) 1 (7.6%)
Breast 5 (2.4%) — 1 (3.4%) — 3 (2.8%) 1 (7.6%)
Other 12 (5.8%) 5 (9.2%) 3 (10.3%) — 4 (3.8%)
GI  gastrointestinal; PCI  percutaneous coronary intervention.
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would bleed to death after surgery if thrombosis did not
occur. However, surgical stress activates the sympathetic
nervous system and causes release of neuroendocrine hor-
mones (epinephrine, norepinephrine, cortisol, renin) and
may indirectly trigger adverse cardiac, vascular, and pulmo-
nary outcomes. Plasma procoagulant clotting factors in-
crease, while fibrinolysis is decreased, resulting in a hyper-
coaguable state (19–21). These physiologic alterations that
occur in the perioperative period may increase the risk of
thrombosis of recently placed stents that might not have had
the opportunity to re-endothelialize.
Placement of a coronary stent results in complete denu-
dation of the endothelial surface; re-endothelialization is
believed to take place within approximately eight weeks
(22,23). It is interesting to note that among patients who
receive stents and who do not undergo surgery, the highest
risk of stent thrombosis is within the first few hours and
days after stent placement, and that even just two weeks of
therapy with a thienopyridine is associated with a very low
rate of stent thrombosis after the thienopyridine is discon-
tinued (24). Therefore, it is likely that partial endotheliali-
zation reduces the risk of stent thrombosis.
Earlier studies. Current recommendations are that revas-
cularization be reserved for patients in whom an indication
for revascularization otherwise exists; it is unusual that
revascularization needs to be performed to “get a patient
through” his or her surgical procedure (25). However, there
are few data about the most appropriate duration that
should elapse after percutaneous revascularization prior to
surgery. In the only study of the issue that has been
reported, Kaluza et al. (10) studied 40 patients and found
that among those who underwent surgery within two weeks
of stent placement the mortality rate was 32%. In contrast,
there were no deaths, MIs, or episodes of stent thrombosis
among the patients in whom 2 weeks elapsed before
surgery.
The current study. The current study is much larger and
confirms an increased risk of major adverse events among
patients in whom surgery is performed early after stent
placement. However, we found that the increased risk
persists for six weeks; there were no major adverse events
among the patients in our study who underwent surgery 6
weeks after stent placement (0%, 95% confidence interval
[CI] 0.0 to 9.0). We believe that our results are consistent
with the time course of re-endothelialization of coronary
arteries after stent placement. It should also be noted that
the increased risk of adverse events following surgery was
much lower than the 32% mortality in the previously
published study (10). In situations where non-cardiac sur-
gery is fairly urgent, our study would suggest that the risk of
major adverse cardiac events is fairly low even when surgery
occurs prior to six weeks post stent placement (4.8%, 95%
Table 6. Procedural Information About the Eight Patients Who Suffered Adverse Ischemic Events
Patient
Stent Placement
Date
Pre-Procedural
Shock
Vessel
Stented Thienopyridines Type of Surgery
1 1993 No LCX none femoral artery repair
2 1996 No LAD, LCX ticlopidine femoral artery repair
3 1996 No LM ticlopidine colonic resection
4 1997 Yes LCX ticlopidine radial artery repair
5 1998 No LAD, RCA clopidogrel hand surgery
6 1999 No SVG to RCA clopidogrel esophagogastrectomy
7 1999 No LAD clopidogrel cystoprostatectomy
8 1999 No LAD clopidogrel left lung lobectomy
LAD  left anterior descending; LCX  left circumflex; LM  left main; RCA  right coronary artery; SVG  saphenous vein graft.
Figure 1. Adverse events within two months of coronary stent placement. MI  myocardial infarction; TVR  target vessel revascularization.
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CI 2.1 to 9.2). This is similar to the low perioperative event
rate previously reported from our institution following
balloon angioplasty (26).
The risk of increased surgical bleeding is an important
issue in patients undergoing non-cardiac surgery after cor-
onary stent placement because of the potent antiplatelet
agents administered to such patients, including aspirin and
a thienopyridine (generally clopidogrel). These agents exert
their antiplatelet effects via different mechanisms, but both
aspirin and thienopyridines result in irreversible inhibition
of platelet function and prolongation of the bleeding time.
The recovery of platelet function occurs from 7 to 10 days
after the discontinuation of treatment (27). We were not
able to identify a relationship between the incidences of
surgical bleeding in patients receiving a single antiplatelet
agent, dual antiplatelet therapy, and no antiplatelet regi-
ment; furthermore, transfusion requirements were similar in
these groups. This was probably due to the relatively small
number of patients in our study, the many different kinds of
surgical procedures performed with greatly varying risks of
bleeding, and the inescapable bias that patients undergoing
surgical procedures associated with a greater risk of bleeding
more frequently discontinued antiplatelet therapy prior to
the surgical procedure, a bias that could not be eliminated in
this study. However, a large prospective study confirmed the
results of smaller retrospective studies indicating that there
is a clear relationship between perioperative bleeding and
administration of a thienopyridine shortly before or at the
time of surgery (28–31). Our data clearly indicate that the
risk of stent thrombosis and other complications is increased
when surgery is performed within six weeks after stent
placement and that, when possible, surgical procedures
ought be delayed for at least six weeks following stent
placement. Delaying surgery will not only allow completion
of a full course of thienopyridine after stent placement,
which has been shown to reduce the frequency of stent
thrombosis, but will also allow for the subsequent recovery
of platelet function, which probably does reduce the risk of
perioperative bleeding even though it could not be demon-
strated in this study (28–31). It should be noted that the
frequency of stent thrombosis following surgery may be
different following coronary brachytherapy, because the
time course of endothelialization of the stent is delayed in
this setting (32).
Finally, we should also mention that some investigators
have proposed the use of heparin-coated stents for the
prevention of early thrombotic occlusion. The results of the
Aspirin Alone Antiplatelet Regimen After Intracoronary
Placement of the Carbostent (ANTARES) study suggest
low rates of stent thrombosis (33). These results are sup-
ported by the findings of Vrolix et al. but do not differ
significantly from recent data suggesting that stent throm-
bosis rates continue to decline (34,35). No randomized
controlled data support the use of heparin-coated stents for
the prevention of stent thrombosis in general, or for
preoperative coronary stenting in particular (36).
Study limitations. This retrospective study is subject to the
limitations of all such studies. However, two limitations
deserve special emphasis. Our ability to determine a rela-
tionship between time to surgery and bleeding, and the
impact of adjunctive antiplatelet and anticoagulant therapy,
are severely limited in this study, as previously described.
Therefore, analysis of the relationship between bleeding and
transfusion requirements on the one hand and antiplatelet
and anticoagulant therapy on the other should be inter-
preted with great caution. Similarly, identification of addi-
tional covariates of stent thrombosis and clinical outcomes is
limited because there were few clinical events. Specifically,
there is a risk of “overfitting” (modeling idiosyncracies in the
sample that may not generalize to other populations) if there
are fewer than 10 events per covariate (37). The second
important limitation relates to the possibility that “sicker”
patients had to proceed to surgery more rapidly and that
delaying surgery could not be expected to eliminate all
adverse events.
Conclusions. Nonetheless, we conclude that delaying sur-
gery for up to six weeks after completing a course of therapy
with a thienopyridine is associated with a lower frequency of
stent thrombosis and other adverse events.
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